Latest Parathyroid gland Stories
Cytochroma has initiated a Phase II clinical trial of CTA018 injection, the company's product candidate for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
NPS Pharmaceuticals has reported positive interim data from an investigator-initiated Phase II proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone for the treatment of hypoparathyroidism.
At the 30th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), positive interim data were presented from an investigator-initiated Phase 2 proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone (PTH 1-84) under development by NPS Pharmaceuticals, Inc.
By DeLellis, Ronald A Mazzaglia, Peter; Mangray, Shamlal Context.-Primary hyperparathyroidism (P-HPT) is one of the most common of all endocrine disorders.
MARKHAM, ON, and OSAKA, Japan, July 30 /PRNewswire/ -- Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S.
CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the receipt of Paragraph IV Certification Notice Letters related to certain drug manufacturers' Abbreviated New Drug Applications (ANDA) submitted to the U.S.
By Richards, Melanie L Grant, Clive S Parathyroid hormone measurement using a two-site immunochemiluminometric assay has allowed for a rapid and accurate technique that has found its way into the operative armamentarium of some parathyroid surgeons.
Changes in a widely used assay (blood test) for parathyroid hormone (PTH) have made its use with the established guidelines for end stage renal disease clinical management both inappropriate and potentially harmful to patients. This research is published in the journal Seminars in Dialysis.
NEW YORK (Reuters Health) - For maintaining calcium metabolism, intake of calcium levels above 800 milligrams daily is probably unnecessary provided that vitamin D status is adequate, according to a report in the Journal of the American Medical Association this week.